Gastric MALT lymphoma - Update on diagnosis and treatment

Best Practice and Research: Clinical Gastroenterology

Volumn 28, Issue 6, 2014, Pages 1069-1077

  Fischbach, Wolfgang ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Diagnosis; Follow up management; Gastric MALT lymphoma; Pathogenesis; Staging; Treatment

Indexed keywords

ANTINEOPLASTIC AGENT; BENDAMUSTINE; CYCLOPHOSPHAMIDE; FLUDARABINE; RITUXIMAB;

ARTICLE; BACTERIAL CLEARANCE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CLINICAL FEATURE; DISEASE ERADICATION; DRUG TREATMENT FAILURE; ERADICATION THERAPY; FOLLOW UP; GASTRIC MARGINAL ZONE LYMPHOMA; HELICOBACTER PYLORI; HISTOLOGY; HUMAN; LARGE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; MULTICENTER STUDY (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); STOMACH CANCER; STOMACH CARCINOGENESIS; VIRUS CARCINOGENESIS; WORLD HEALTH ORGANIZATION; GASTROINTESTINAL ENDOSCOPY; HELICOBACTER INFECTIONS; LYMPHOMA, B-CELL, MARGINAL ZONE; MICROBIOLOGY; PATHOGENICITY; PROGNOSIS; STOMACH NEOPLASMS;

ENDOSCOPY, GASTROINTESTINAL; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; LYMPHOMA, B-CELL, MARGINAL ZONE; PROGNOSIS; STOMACH NEOPLASMS;

EID: 84927927608     PISSN: 15216918     EISSN: 15321916     Source Type: Journal    
DOI: 10.1016/j.bpg.2014.09.006     Document Type: Review

References (46)

1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumours of haematopoetic and lymphoid tissues. 4th ed., vol. 4. Lyon: IARC Press; 2008. p. 158-66. 214-217.
2. Wotherspoon A, Ortiz-Hidalgo C, Falzon MR, Isaacson PG. Helicobacter pylori associated gastritis and primary B-cell lymphoma. Lancet 1991;338: 1175-6.
3. Stolte M. Helicobacter pylori gastritis and gastric MALT-lymphoma. Lancet 1992;339: 745.
4. Eck M, SchmaußerW, Haas R, Greiner A, Czub S, Müller-Hermelink HK. MALT-type lymphoma of the stomach is associated with Helicobacter pylori strains expressing the CagA protein. Gastroenterology 1997;112: 1482-6.
5. Hellmig S, Bartscht T, Fischbach W, Ott SJ, Rosenstiel P, Klapper W, et al. Germline variations of the MALT1 gene as risk factors in the development of primary gastric B-cell lymphoma. Eur J Cancer 2009;45: 1865-70.
6. Jacobs G, Hellmig S, Huse K, Titz A, Franke A, Kwiatkowski R, et al. Polymorphisms in the 3'-untreated region of the CDH1 gene are a risk factor for primary gastric diffuse large B-cell lymphoma. Haematologica 2011;96(7): 987-99.
7. Wotherspoon AC, Doglioni C, Diss TC, Pan L, Moschini A, de Boni M, et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue. Lancet 1993;342: 575-7.
8. Kolve M, Fischbach W, Greiner A, Wilms K. Differences in endoscopic and clinicopathological features of primary and secondary gastric non-Hodgkin's lymphoma. Gastrointest Endosc 1999;49: 307-15.
9. Cogliatti SB, Schmid U, Schumacher U, Eckert F, Hansmann ML, Hedderich J, et al. Primary B-cell gastric lymphoma: A clinico-pathological study of 145 patients. Gastroenterology 1991;101: 1159-70.
10. Radaszkiewicz Th, Dragosics B, Bauer P. Gastrointestinal malignant lymphomas of the mucosa-associated lymphoid tissue. Factors relevant to prognosis. Gastroenterology 1992;102: 1628-38.
11. Ruskone-Fourmestraux A, Aegerter P, Delmer A, Brousse N, Galian A, Rambaud JC. Primary digestive tract lymphoma: A prospective multicentric study of 91 patients. Gastroenterology 1993;105: 1662-72.
12. Schechter NR, Portlock CS, Yahalom J. Treatment of mucosa-associated lymphoid tissue lymphoma of the stomach with radiation alone. J Clin Oncol 1998;16: 916-1921.
13. Fischbach W, Dragosics B, Koelve-Goebeler ME, Ohmann C, Greiner A, Yang Q, et al. Primary gastric B-cell lymphoma: Results of a prospective multicenter study. Gastroenterology 2000;119: 1191-202.
14. Koch P, delValle F, Berdel WE,Willich NA, Reers B, HiddemannW, et al. Primary gastrointestinal non-Hodgkins lymphoma: I. Anatomic and histologic distribution, clinical features, and survival data of 371 patients registered in the german multicenter study GIT NHL 01/92. J Clin Oncol 2001;19: 3861-73.
15. Koch P, Probst A, Berdel WE, Willich NA, Reinartz G, Brockmann J, et al. Treatment results in localized primary gastric lymphoma: Data of patients registered within the German multicenter study (GIT NHL 02/96). J Clin Oncol 2005;23: 7050-9.
16. Tsang RW, Gospodarowicz MK, Pintilie M. Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome. J Clin Oncol 2003;21: 4157-64.
17. Liu H, Ye H, Ruskone-Fourmestraux A, De Jong D, Pileri S, Thiede C, et al. T(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradication. Gastroenterrology 2002;122: 1286-94.
18. Yeh KH, Kuo SH, Chen LT, Mao TL, Doong SL, Wu MS, et al. Nuclear expression of BCL10 or nuclear factor kappa B helps predict Helicobacter pylori-independent status of low-grade gastric mucosa-associated lymphoid tissue lymphomas with or without t(11;18)(q21;q21). Blood 2005;106: 1037-41.
19. Fischbach W, Malfertheiner P, Hoffmann JC, Bolten W, Bornschein J, Götze O, et al. S3-guideline "Helicobacter pylori and gastroduodenal ulcer disease" of the German society for digestive and metabolic diseases (DGVS) in cooperation with the German society for hygiene and microbiology, society for pediatric gastroenterology and nutrition e.V., German society for rheumatology, AWMF-registration-no. 021/001. Z Gastreoenterol 2009;47(12): 1230-63.
20. Ruskoné-Fourmestraux A, Fischbach W, Aleman BMP, Boot H, Du MQ, Megraud F, et al. EGILS consensus report. Gastric extranodal marginal zone B cell lymphoma of MALT. Gut 2011;60: 747-58.
21. Musshoff K. Clinical staging classification of non-Hodgkin's lymphomas. Strahlentherapie 1977;153: 218-21.
22. Ruskone-Fourmestraux A, Dragosics B, Morgner A, Wotherspoon A, de Jong D. Paris staging system for primary gastrointestinal lymphomas. Gut 2003;52: 912-3.
23. Nakamura S, Sugiyama T, Matsumoto T, Iijima K, Ono S, Tajika M, et al. Long-term clinical outcome of gastric MALT lymphoma after eradication of Helicobacter pylori: A multicentre cohort follow-up study of 420 patients in Japan. Gut 2012;61: 507-13.
24. Zullo A, Hassan C, Cristofari F, Andriani A, De Francesco V, Ierardi E, et al. Effects of Helicobacter pylori eradication on early stage gastric mucosa-associated lymphoid tissue lymphoma. Clin Gastroenterol Hepatol 2010;8: 105-10.
25. Zullo A, Hassan C, Andriani A, Cristofari F, De Francesco V, Ierardi E, et al. Eradication therapy for Helicobacter pylori in patients with gastric MALT lymphoma: A pooled data analysis. Am J Gastroenterol 2009;104: 1932-7.
26. Raderer M, Streubel B,Wöhrer S, Häfner M, Chott A. Successful antibiotic treatment of Helico-bacter pylori negative gastric mucosa associated lymphoid tissue lymphomas. Gut 2006;55: 616-8.
27. Al-Taie O, Al-Taie E, Fischbach W. Patients with Helicobacter pylori negative gastric marginal zone B-cell lymphoma (MZBCL) of MALT have a good prognosis. Z Gastroenterol 2014;52: 1-5.
28. Zullo A, Hassan C, Ridola L, De Francesco V, Rossi L, Tomao S, et al. Eradication therapy in Helicobacter pylori-negative, gastric low-grade mucosa-associated lymphoid tissue lymphoma patients. A systematic review. J Clin Gastroenterol 2013; 47(10): 824-7.
29. Fischbach W, Goebeler-Kolve ME, Dragosics B, Greiner A, Stolte M. Long term outcome of patients with gastric marginal zone B cell lymphoma of mucosa associated lymphoid tissue (MALT) following exclusive Helicobacter pylori eradication: Experience from a large prospective series. GUT 2004;53: 34-7.
30. Wündisch T, Thiede C, Morgner A, Dempfle A, Günther A, Liu H, et al. Long-term follow-up of gastric MALT lymphoma after Helicobacter Pylori eradication. J Clin Oncol 2005;23(31): 8018-24.
31. Wündisch T, Dieckhoff P, Greene B, Thiede C, Wilhelm C, Stolte M, et al. Second cancers and residual disease in patients treated for gastric mucosa-associated lymphoid tissue lymphoma by Helicobacter pylori eradication and followed for 10 years. Gastroenterology 2012;143(4): 936-42.
32. Fischbach W, Goebeler-Kolve M, Starostik P, Greiner A, Müller-Hermelink HK. Minimal residual low-grade gastric MALTtype lymphoma after eradication of Helicobacter pylori. Lancet 2002;360: 547-8.
33. Fischbach W, Goebeler ME, Ruskone-Fourmestraux A, Wündisch T, Neubauer A, Raderer M, et al. Most patients with minimal histological residuals of gastric MALT lymphoma after successful eradication of Helicobacter pylori can be safely managed by a watch-and-wait strategy. Experience from a large international series. Gut 2007;56: 1685-7.
34. Copie-Bergman C, Gaulard P, Lavergne-Slove A, Brousse N, Fléjou JF, Dordonne K, et al. Proposal for a new histological grading system for post-treatment evaluation of gastric MALT lymphoma. Gut 2003;52: 1656.
35. Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grünhagen U, Losem C, et al. Bendamustine plus rituximab versus CHOP plus rituximabas first-line treatment for patients with indolent and mantle-cell lymphomas: An open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013;381: 1203-10.
36. Fischbach W. MALT lymphoma: Forget surgery? Dig Dis 2013;31: 38-43.
37. Cirocchi R, Farinella E, Trastulli S, et al. Surgical treatment of primary gastrointestinal lymphoma.World J Surg Oncol 2011; 9: 145-51.
38. FischbachW, Schramm S, Goebeler E. Outcome and quality of life favour a conservative treatment of patients with primary gastric lymphoma. Z Gastroenterol 2011;49: 430-5.
39. Akamatsu T, Mochizuki T, Okiyama Y, Matsumoto A, Miyabayashi H, Ota H. Comparison of localized gastric mucosaassociated lymphoid (MALT) lymphoma with and without Helicobacter pylori infection. Helicobacter 2006;11: 86-95.
40. Chung SJ, Kim JS, Kim H, Kim SG, Kim CW, Jung HC, et al. Long-term clinical outcome of Helicobacter pylori-negative gastric mucosa-associated lymphoid tissue lymphoma is comparable to that of H. pylori-positive lymphoma. J Clin Gastroenterol 2009;43: 312-7.
41. Park HS, Kim YJ, Yang WI, Suh CO, Lee YC. Treatment outcome of localized Helicobacter pylori-negative low-grade gastric MALT lymphoma. World J Gastroenterol 2010;16(17): 2158-62.
42. Morgner A, Miehlke S, Fischbach W, Schmitt W, Müller-Hermelink HK, Greiner A, et al. Complete remission of primary high-grade B-cell gastric lymphoma after cure of Helicobacter pylori infection. J Clin Oncol 2001;19: 2041-8.
43. Kuo SH, Yeh KH, Wu MS. Helicobacter pylori eradication therapy is effective in the treatment of early-stage H. pyloripositive diffuse large B-cell lymphomas. Blood 2012;119: 4838-44.
44. Aviles A, Nambo MJ, Neri N, Huerta-Guzman J, Cuadra I, Alvarado I, et al. The role of surgery in primary gastric lymphoma: Results of a controlled clinical trial. Ann Surg 2004;240(1): 44-50.
45. Bonnet C, Fillet G, Mounier N, Ganem G, Molina TJ, Thiéblemont C, et al. CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: A study by the Groupe d'-Etude des Lymphomes de l'Adulte. J Clin Oncol 2007;25(7): 787-92.
46. Capelle LG, de Vries AC, Looman CWN, Casparie MK, Meijer GA, Kuipers EJ. Gastric MALT lymphoma: Epidemiology and high adenocarcinoma risk in a nation-wide study. Eur J Cancer 2008;44: 2470-6.